Javier L. Baylon

Javier L. Baylon

Auto-generated profile, based on publicly available information

Javier L. Baylon

Bristol-Myers Squibb Company, San Diego, California 92121, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2019 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
JBJavier L. Baylon
Javier L. Baylon
NCNicholas A. Cilfone
Nicholas A. Cilfone
JGJeffrey R. Gulcher
Jeffrey R. Gulcher
TCThomas W. Chittenden
Thomas W. Chittenden

14 December 2017 in Biochemistry
Verified
Journal Article
Open access
IDIlia Denisov
Ilia Denisov
JBJavier L. Baylon
Javier L. Baylon
YGYelena V. Grinkova
Yelena V. Grinkova
Emad TajkhorshidEmad Tajkhorshid
Emad Tajkhorshid
SSStephen Sligar
Stephen Sligar
Heterotropic interactions between atorvastatin (ARVS) and dronedarone (DND) have been deciphered using global analysis of the results of binding and turnover experiments for pure drugs and their mixtures. The in vivo presence of atorvastatin lactone (ARVL) was explicitly taken into account by using pure ARVL in analogous experiments. Both ARVL and ARVS inhibit DND binding and metabolism, while a significantly higher affinity of CYP3A4 for ARVL makes the latter the main modulator of activity (effector) in this system. Molecular dynamics simulations reveal significantly different modes of interactions of DND and ARVL with the substrate binding pocket and with a peripheral allosteric site. Interactions of both substrates with residues F213 and F219 at the allosteric site play a critical role in the communication of conformational changes induced by effector binding to productive binding of the substrate at the catalytic site.

19 March 2024 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
DWDahlia R. Weiss
Dahlia R. Weiss
JBJavier L. Baylon
Javier L. Baylon
EEEthan D. Evans
Ethan D. Evans
APAnthony Paiva
Anthony Paiva
GEGerry Everlof
Gerry Everlof
FBFabio Broccatelli
Fabio Broccatelli

13 August 2024 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
FBFabio Broccatelli
Fabio Broccatelli
VVVijayabhaskar Veeravalli
Vijayabhaskar Veeravalli
DCDaniel Cashion
Daniel Cashion
JBJavier L. Baylon
Javier L. Baylon
FLFranco Lombardo
Franco Lombardo
LJLei Jia
Lei Jia

22 February 2022 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
JBJavier L. Baylon
Javier L. Baylon
OUOleg Ursu
Oleg Ursu
AMAnja Muzdalo
Anja Muzdalo
AWAnne Mai Wassermann
Anne Mai Wassermann
GAGregory L. Adams
Gregory L. Adams
DBDanny Asher Bitton
Danny Asher Bitton

3 June 2025 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JBJavier L. Baylon
Javier L. Baylon
MCMatthew J. Chalkley
Matthew J. Chalkley
TSTony Siu
Tony Siu
WSWilson Shou
Wilson Shou
YSYongnian Sun
Yongnian Sun
DWDahlia R. Weiss
Dahlia R. Weiss